Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs

Addiction

Volumn 114, Issue 1, 2019, Pages 150-166

  Grebely, Jason ^a   Larney, Sarah ^b   Peacock, Amy ^b   Colledge, Samantha ^b   Leung, Janni ^b,c   Hickman, Matthew ^d   Vickerman, Peter ^d   Blach, Sarah ^e   Cunningham, Evan B ^a   Dumchev, Kostyantyn ^f   Lynskey, Michael ^g   Stone, Jack ^d   Trickey, Adam ^d   Razavi, Homie ^e   Mattick, Richard P ^b   Farrell, Michael ^b   Dore, Gregory J ^a   Degenhardt, Louisa ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e CDA Foundation   (United States)

^f UKRAINIAN INSTITUTE ON PUBLIC HEALTH POLICY   (Ukraine)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Estimates; HCV; IDU; injecting drug use; PWID; viraemic

Indexed keywords

ADOLESCENT; ADULT; EASTERN EUROPE; FAR EAST; FEMALE; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; NORTH AMERICA; PREVALENCE; SOUTHEAST ASIA; SUBSTANCE ABUSE; YOUNG ADULT;

ADOLESCENT; ADULT; ASIA, SOUTHEASTERN; EUROPE, EASTERN; FAR EAST; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 85053205178     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14393     Document Type: Review

References (19)

1. World Health Organization (WHO). Global Hepatitis Report 2017. Geneva: WHO; 2017
2. Nelson P. K., Mathers B. M., Cowie B., Hagan H., Des Jarlais D., Horyniak D. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571–583
3. Morris M. D., Shiboski S., Bruneau J., Hahn J. A., Hellard M., Prins M. et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis 2017; 64: 860–869
4. Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K. J. et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9: e103345
5. Hagan H., Pouget E. R., Des Jarlais D. C., Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 1099–1109
6. Page K., Morris M. D., Hahn J. A., Maher L., Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013; 57: S32–S38
7. Degenhardt L., Peacock A., Colledge S., Leung J., Grebely J., Vickerman P. et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 2017; 5: e1192–e1207
8. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161–176
9. Grebely J., Page K., Sacks-Davis R., van der Loeff M. S., Rice T. M., Bruneau J. et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59: 109–120
10. Mathers B. M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S. A. et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733–1745
11. Platt L., Minozzi S., Reed J., Vickerman P., Hagan H., French C. et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis. Addiction 2017; https://doi.org/10.1111/add.14012
12. Bajis S., Dore G. J., Hajarizadeh B., Cunningham E. B., Maher L., Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy 2017; 47: 34–46
13. Grebely J., Dore G. J., Morin S., Rockstroh J. K., Klein M. B. Elimination of HCV as a public health concern among people who inject drugs by 2030—what will it take to get there? J Int AIDS Soc 2017; 20: 22146
14. Smith D. J., Jordan A. E., Frank M., Hagan H. Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC Infect Dis 2016; 16: 471
15. Alavi M., Raffa J. D., Deans G. D., Lai C., Krajden M., Dore G. J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int 2014; 34: 1198–1206
16. Iversen J., Grebely J., Topp L., Wand H., Dore G., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999–2011. J Viral Hepatol 2014; 21: 198–207
17. Mehta S. H., Genberg B. L., Astemborski J., Kavasery R., Kirk G. D., Vlahov D. et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126–133
18. Grebely J., Raffa J. D., Lai C., Krajden M., Kerr T., Fischer B., et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepatol 2009; 16: 352–358
19. Strathdee S. A., Latka M., Campbell J., O'Driscoll P. T., Golub E. T., Kapadia F. et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40: S304–S312